CLINICAL TRIALS PROFILE FOR HEPARIN CALCIUM
✉ Email this page to a colleague
All Clinical Trials for heparin calcium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000472 ↗ | Thrombolysis in Myocardial Ischemia Trial (TIMI III) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1989-04-01 | The Thrombolysis in Myocardial Ischemia Trial (TIMI III) focused on unstable angina and non-Q-wave myocardial infarction. The trial was designed to determine by coronary arteriography the incidence of coronary thrombi in these conditions and the response of these thrombi to tissue-type plasminogen activator (t-PA) in TIMI IIIA and the effects of thrombolytic therapy and of an early invasive strategy on clinical outcome in TIMI IIIB. There was also a registry with two components. A roster enumerated all patients with unstable angina or non-Q-wave myocardial infarction enrolled at cooperating hospitals. From the roster, a study population of 1,893 subjects was selected and followed prospectively for the year to determine incidence of death or myocardial infarction. |
| NCT00000473 ↗ | Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty? | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1989-07-01 | To determine whether a dietary supplement of n-3 polyunsaturated fatty acids (PUFAs) derived from fish oil would decrease the restenosis rate in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). |
| NCT00004786 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis | Completed | University of Pittsburgh | Phase 3 | 1995-12-01 | OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis. |
| NCT00004786 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis | Completed | National Center for Research Resources (NCRR) | Phase 3 | 1995-12-01 | OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis. |
| NCT00212043 ↗ | Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma | Completed | Eli Lilly and Company | Phase 2 | 2000-07-01 | Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer |
| NCT00212043 ↗ | Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma | Completed | National University Hospital, Singapore | Phase 2 | 2000-07-01 | Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer |
| NCT00378781 ↗ | Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection | Withdrawn | National Cancer Institute (NCI) | N/A | 1969-12-31 | RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection. It is not yet known whether heparin is more effective than M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection. PURPOSE: This randomized clinical trial is studying heparin to see how well it works compared with M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for heparin calcium
Condition Name
Clinical Trial Locations for heparin calcium
Trials by Country
Clinical Trial Progress for heparin calcium
Clinical Trial Phase
Clinical Trial Sponsors for heparin calcium
Sponsor Name
